Vivos Therapeutics
VVOS
18 hedge funds and large institutions have $5.45M invested in Vivos Therapeutics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
80% more funds holding
Funds holding: 10 → 18 (+8)
51% more capital inflows, than outflows
Capital inflows: $2.83M | Capital outflows: $1.87M
0.38% more ownership
Funds ownership: 4.13% → 4.51% (+0.38%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avalon Investment & Advisory
Houston,
Texas
|
+$1.21M |
| 2 |
Griffin Asset Management
New York
|
+$426K |
| 3 |
Royce & Associates
New York
|
+$343K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$221K |
| 5 |
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$440K |
| 2 |
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$328K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$304K |
| 4 |
MYDA Advisors
Woodmere,
New York
|
-$260K |
| 5 |
Maven Securities
St Helier,
Jersey
|
-$197K |
VVOS Hedge Fund Activity: Q1 2021 in Review
18 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q1 2021, worth a combined $5.45M — up 26% from $4.32M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new VVOS positions and 6 closed out — a net gain of 8 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Avalon Investment & Advisory, opening a new position worth an estimated $1.21M. The largest seller was Walleye Capital, exiting entirely with an estimated $440K sold.
- 18 institutional investors held Vivos Therapeutics (VVOS) as of Q1 2021, up from 10 in Q4 2020.
- Funds reported $5.45M of Vivos Therapeutics stock for Q1 2021, up 26% quarter-over-quarter.
- 14 funds opened new Vivos Therapeutics positions in Q1 2021 and 6 closed out, a net change of +8 holders.
- The largest Vivos Therapeutics buyer in Q1 2021 was Avalon Investment & Advisory, an estimated $1.21M added.
- The largest Vivos Therapeutics seller in Q1 2021 was Walleye Capital, an estimated $440K sold.
Based on aggregated 13F filings for Q1 2021.